Litcius/Paper detail

1325P Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations

James Chih‐Hsin Yang, M. Wang, C-H. Chiu, P-C. Hsu, Paul Mitchell, Chia‐Lun Chang, T.M. Kim, Thomas John, Laurent Greillier, Lyudmila Bazhenova, Enric Carcereny, Alexander I. Spira, Byoung Yong Shim, K.H. Lee, Manuel Cobo, François Ghiringhelli, C. W. Yip, Jie Xiong, Pasi A. Jänne, C. Zhou

2023Annals of Oncology12 citationsDOIOpen Access PDF

Topics & Concepts

MedicineInternal medicineDiscontinuationOncologyPhases of clinical researchResponse Evaluation Criteria in Solid TumorsCancerFirst lineChemotherapyLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesCancer Genomics and Diagnostics
1325P Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations | Litcius